Baidu
map

BMJ:乳腺癌患者化疗期间远程主动毒性管理可减少化疗不良事件风险

2021-12-13 MedSci原创 MedSci原创

早期乳腺癌患者化疗期间远程主动毒性管理可减少化疗不良事件导致的急诊或住院次数。鉴于新冠肺炎疫情的不确定性,肿瘤患者治疗期间远程管理的重要性将愈加显著

化疗是许多肿瘤治疗的重要手段,化疗相关毒性是其主要不良事件。研究发现,化疗期间紧急医疗干预十分常见,在常规接受治疗的化疗患者中,42%至少经历过1次化疗不良事件导致的急诊或住院。许多化疗毒性是可预测的,并可以通过早期干预来预防或改善。近日研究人员考察了早期乳腺癌患者化疗期间远程主动毒性管理的有效性。

本次研究在加拿大安大略省的20个肿瘤中心开展,患者随机接受化疗毒性远程管理或常规护理,参与者为接受辅助或新辅助化疗的早期乳腺癌患者,患者填写自我报告结果问卷。远程管理组在每个化疗周期后的两个时间点,对常见毒性进行前瞻性、标准化、护士主导的电话管理。研究的主要终点为整个化疗期间患者因化疗毒性接受急诊就诊或住院的平均次数,次要终点为患者报告结果包括毒性、自理能力和生活质量

干预组(n=944)和对照组(n=1214)参与者的基线特征相似,22%的患者年龄大于65岁。每个肿瘤中心接受干预的患者的百分比在50-86%。干预组患者在治疗期间因化疗毒性接受急诊就诊或住院的平均次数为0.91次(标准差0.28),对照组为0.94次(0.040),47%(2158例患者中有1014例)的患者在化疗期间至少有1次急诊或住院经历。在完成患者报告结果问卷的580名参与者中,干预组中48%(278例患者中有134例)的患者报告了至少一种3级毒性事件,对照组为58%(283例中的163例)。组间其他次要终点无显著差异。

组间化疗相关3级不良事件风险差异

研究认为,早期乳腺癌患者化疗期间远程主动毒性管理可减少化疗不良事件导致的急诊或住院次数。鉴于新冠肺炎疫情的不确定性,肿瘤患者治疗期间远程管理的重要性将愈加显著

原始出处:

Monika K Krzyzanowska et al. Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial.BMJ. 08 December, 2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849343, encodeId=900918493433f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 21 08:56:41 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007414, encodeId=9d4e200e414e6, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Apr 12 13:56:41 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214267, encodeId=cde1121426e55, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=33544, encryptionId=adf23354483, topicName=化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:24:02 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571307, encodeId=16ad15e130730, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Dec 15 09:56:41 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079834, encodeId=dae010e983411, content=疗是许多肿瘤治疗的重要手段,化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:15 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079682, encodeId=8be310e96827d, content=协议学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 20:44:11 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079660, encodeId=7dc810e96606c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Dec 13 19:33:02 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2022-11-21 gaoxiaoe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1849343, encodeId=900918493433f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 21 08:56:41 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007414, encodeId=9d4e200e414e6, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Apr 12 13:56:41 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214267, encodeId=cde1121426e55, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=33544, encryptionId=adf23354483, topicName=化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:24:02 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571307, encodeId=16ad15e130730, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Dec 15 09:56:41 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079834, encodeId=dae010e983411, content=疗是许多肿瘤治疗的重要手段,化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:15 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079682, encodeId=8be310e96827d, content=协议学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 20:44:11 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079660, encodeId=7dc810e96606c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Dec 13 19:33:02 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1849343, encodeId=900918493433f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 21 08:56:41 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007414, encodeId=9d4e200e414e6, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Apr 12 13:56:41 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214267, encodeId=cde1121426e55, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=33544, encryptionId=adf23354483, topicName=化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:24:02 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571307, encodeId=16ad15e130730, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Dec 15 09:56:41 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079834, encodeId=dae010e983411, content=疗是许多肿瘤治疗的重要手段,化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:15 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079682, encodeId=8be310e96827d, content=协议学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 20:44:11 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079660, encodeId=7dc810e96606c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Dec 13 19:33:02 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1849343, encodeId=900918493433f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 21 08:56:41 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007414, encodeId=9d4e200e414e6, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Apr 12 13:56:41 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214267, encodeId=cde1121426e55, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=33544, encryptionId=adf23354483, topicName=化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:24:02 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571307, encodeId=16ad15e130730, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Dec 15 09:56:41 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079834, encodeId=dae010e983411, content=疗是许多肿瘤治疗的重要手段,化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:15 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079682, encodeId=8be310e96827d, content=协议学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 20:44:11 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079660, encodeId=7dc810e96606c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Dec 13 19:33:02 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1849343, encodeId=900918493433f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 21 08:56:41 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007414, encodeId=9d4e200e414e6, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Apr 12 13:56:41 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214267, encodeId=cde1121426e55, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=33544, encryptionId=adf23354483, topicName=化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:24:02 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571307, encodeId=16ad15e130730, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Dec 15 09:56:41 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079834, encodeId=dae010e983411, content=疗是许多肿瘤治疗的重要手段,化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:15 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079682, encodeId=8be310e96827d, content=协议学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 20:44:11 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079660, encodeId=7dc810e96606c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Dec 13 19:33:02 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-14 查查佳佳

    疗是许多肿瘤治疗的重要手段,化疗相关毒

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1849343, encodeId=900918493433f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 21 08:56:41 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007414, encodeId=9d4e200e414e6, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Apr 12 13:56:41 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214267, encodeId=cde1121426e55, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=33544, encryptionId=adf23354483, topicName=化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:24:02 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571307, encodeId=16ad15e130730, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Dec 15 09:56:41 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079834, encodeId=dae010e983411, content=疗是许多肿瘤治疗的重要手段,化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:15 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079682, encodeId=8be310e96827d, content=协议学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 20:44:11 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079660, encodeId=7dc810e96606c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Dec 13 19:33:02 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-13 今天明天aaaaaaf9

    协议学习学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1849343, encodeId=900918493433f, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Nov 21 08:56:41 CST 2022, time=2022-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2007414, encodeId=9d4e200e414e6, content=<a href='/topic/show?id=609c2048199' target=_blank style='color:#2F92EE;'>#不良事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20481, encryptionId=609c2048199, topicName=不良事件风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Tue Apr 12 13:56:41 CST 2022, time=2022-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1214267, encodeId=cde1121426e55, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者<a href='/topic/show?id=adf23354483' target=_blank style='color:#2F92EE;'>#化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23725, encryptionId=73c423e2572, topicName=乳腺癌), TopicDto(id=33544, encryptionId=adf23354483, topicName=化疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Mon Apr 25 22:24:02 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571307, encodeId=16ad15e130730, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Wed Dec 15 09:56:41 CST 2021, time=2021-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079834, encodeId=dae010e983411, content=疗是许多肿瘤治疗的重要手段,化疗相关毒, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIrrxxDxnLic8t6EAs38Qfwo6H2h6JMleIgb9OSYf6LMnVDkQEqUXWoSDWboibjhOBI9SJDTXweqQIA/132, createdBy=50aa5321359, createdName=查查佳佳, createdTime=Tue Dec 14 09:16:15 CST 2021, time=2021-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079682, encodeId=8be310e96827d, content=协议学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210821/285a12750b6f479abbc2cb84dfb7885e/1073447e075b4528b9a08483aefe5172.jpg, createdBy=79975576266, createdName=今天明天aaaaaaf9, createdTime=Mon Dec 13 20:44:11 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1079660, encodeId=7dc810e96606c, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Mon Dec 13 19:33:02 CST 2021, time=2021-12-13, status=1, ipAttribution=)]
    2021-12-13 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

J Clin Oncol:乳腺癌化疗后大脑认知功能减退的罪魁祸首

化疗脑:20%~40%的乳腺癌患者化疗后可出现记忆力、注意力、思维等大脑认知功能减退,可能持续至康复期并干扰日常生活技能和生活质量。在化疗前预测化疗后有脑功能减退风险的乳腺癌患者,将有助于改善患者治疗

Clin Cancer Res:曲妥珠单抗联合内分泌或化疗作为HR+HER2+转移性乳腺癌的一线治疗的疗效对比

曲妥珠单抗联合内分泌治疗作为激素受体阳性、HER2阳性的转移性乳腺癌的一线方案的效果不劣于曲妥珠单抗联合化疗

JCO:派姆单抗 vs 化疗作为二线疗法对晚期食道癌患者生活质量的影响

CPS≥10分的食道鳞状细胞癌患者采用派姆单抗单药或化疗维持治疗的健康相关生活质量无明显差异

Exp Hematol:急性髓系白血病化疗损伤后免疫成分及其与血液学恢复的关系

化疗后 BM 中的 NK/CD4CM 比率与随后中性粒细胞恢复的时间显着相关(Spearman's ρ = -0.723,p < 0.001,FDR < 0.01)。

Front Oncol:化疗对转移性前列腺癌患者的总生存期影响

该真实世界数据研究表明,化疗可以改善转移性前列腺癌患者的总生存期。但是,总生存获益的幅度无法与III期试验相媲美。

Eur Urol:转移去势抵抗性前列腺癌中,激素治疗与化疗获益的预测性基因组生物标志物调查

新的激素疗法(NHTs),如阿比特龙和恩扎鲁胺,以及基于紫杉类药物的化疗,是治疗转移去势抵抗性前列腺癌(mCRPC)的常用系统疗法。

Baidu
map
Baidu
map
Baidu
map